Outlook Therapeutics, Inc.
OTLK • NASDAQ
Outlook Therapeutics, Inc. is a biotechnology company in the healthcare sector trading on NASDAQ, led by CEO Robert Charles Jahr, with a market cap of $21.8M.
CEORobert Charles Jahr
Next Earnings
Upcoming earnings announcement for Outlook Therapeutics, Inc.
Date
Thursday, May 14, 2026 (in a month)
Timing
After Market Close (5:00 PM New York)
Fiscal Period
Q2 2026
EPS Estimate
-$0.12
Revenue Estimate
$4.4M
Earnings History
Past 12 earnings reports for Outlook Therapeutics, Inc.
| Date | Period | EPS | EPS Surprise | Revenue | Rev. Surprise | Filing |
|---|---|---|---|---|---|---|
| Feb 17, 2026 | Q1 2026 | -$0.22Est: -$0.17 | -29.4% | -$1.2MEst: $3.4M | -135.3% |  10-Q |
| Dec 19, 2025 | Q4 2025 | -$0.19Est: -$0.24 | +20.8% | -$91.8KEst: $6.0M | -101.5% | 10-K |
| Aug 14, 2025 | Q3 2025 | -$0.44Est: -$0.40 | -10.0% | $1.5MEst: $2.0M | -25.4% | 10-Q |
| May 15, 2025 | Q2 2025 | -$0.40Est: -$0.55 | +27.3% | -Est: $702.6K | -100.0% | 10-Q |
| Feb 14, 2025 | Q1 2025 | -$0.89Est: -$0.52 | -71.2% | - | — | 10-Q |
| Dec 27, 2024 | Q4 2024 | -$0.94Est: -$0.85 | -10.6% | - | — | 10-K/A |
| Aug 14, 2024 | Q3 2024 | -$0.83Est: -$1.01 | +17.8% | - | — | 10-Q |
| May 15, 2024 | Q2 2024 | -$1.55Est: -$0.85 | -82.4% | - | — | 10-Q |
| Feb 14, 2024 | Q1 2024 | -$0.80 | — | - | — | 10-Q |
| Dec 22, 2023 | Q4 2023 | -$1.00 | — | - | — | — |
| Aug 14, 2023 | Q3 2023 | -$1.60Est: -$1.00 | -60.0% | - | — | — |
| May 15, 2023 | Q2 2023 | -$0.60Est: -$1.20 | +50.0% | - | — | — |